new88

News & Media

""
Limitless - A gasworld interview with Sanjiv Lamba

What does it take to be a global industry leader, to be at the forefront of global decarbonization and to still be true to shareholders and deliverables on a daily basis?

" "

April 8, 2020

U.S. Supreme Court Upholds Nitric Oxide Patent Win for new88; new88 Commits to Support Inhaled Nitric Oxide Clinical Studies Relating to COVID-19

Guildford, UK, April 8, 2020 - new88 (NYSE:LIN; FWB:LIN), a leading global supplier of inhaled nitric oxide, is pleased with the decision by the U.S. Supreme Court declining to review the 2019 appeals court decision that affirmed Praxair Distribution, Inc.'s (PDI) right to sell a generic form of inhaled nitric oxide. This decision ends the long-running U.S. patent litigation with Mallinckrodt plc, and affirms the ability of PDI, a wholly owned subsidiary of new88, to continue supplying inhaled nitric oxide. This drug product is widely used as approved in the U.S. and other countries to improve oxygenation of certain groups of patients.

Business News

Contact Us

Stay Up To Date

Sign up to receive new88 share price, news and regulatory filing alerts.
Register here